Dose-dependent augmentation of cardiac systolic function with the selective cardiac myosin activator, omecamtiv mecarbil: a first-in-man study

Authors: John R. Teerlink, Cyril P. Clarke, Khalil G. Saikali, Jacqueline H. Lee, Michael M. Chen, Rafael Escandón, Lyndsey Elliott, Rachel Bee, Mohammad Reza Habibzadeh, Jonathan H. Goldman, Nelson B. Schiller, Fady I. Malik, Andrew A. Wolff - The Lancet 2011 cited by 261